Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 2
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
2| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9187489 | IBTROZItaletrectinib adipate | substance, product | Jun 2033 |
| 9751887 | IBTROZItaletrectinib adipate | substance, product | Jun 2033 |
| Product | Exclusivity | Until |
|---|---|---|
| IBTROZITALETRECTINIB ADIPATE | ODE-544 Orphan drug | Jun 2032 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| IBTROZI | taletrectinib | capsule, oral | 84651-200NDA |
Enquiry
Common questions
- Is Nuvation Bio Inc. FDA approved?
- Nuvation Bio Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Nuvation Bio Inc. make?
- 1 product is listed under Nuvation Bio Inc. in the openFDA NDC Directory, most often as capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.